Start of cohort expansion of Phase I clinical trial testing the combination of lirilumab and nivolumab in selected solid tumors
Innate Pharma continues Phase II trial with lirilumab as planned, following Data and Safety Monitoring Board recommendation
Innate Pharma acquires full rights to ANTI-NKG2A checkpoint inhibitor from Novo Nordisk A/S
Innate Pharma initiates IPH43 program to develop «first-in-class» anti-MICA antibody
Preclinical data opening new perspectives for development of lirilumab in combination to be presented at ASH
Three posters on the anti-KIR program to be presented at the upcoming ASH annual meeting
Launch of IND-Enabling studies for IPH4102
Innate Pharma announces first DSMB review of ongoing EffiKIR Phase II trial with lirilumab
Innate Pharma presents new data for proprietary programs targeting TLR3 and KIR3DL2
Phase I clinical trial of IPH2102/BMS-986015 in combination with ipilimumab announced
